<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Bloomsbury Burger Therapeutics â€” Project Wiki</title>
<link rel="stylesheet" href="style.css">
<script>
  window.MathJax = {
    tex: { inlineMath: [['$','$'], ['\\(','\\)']], displayMath: [['$$','$$'], ['\\[','\\]']] },
    options: { skipHtmlTags: ['script','noscript','style','textarea','pre'] },
    startup: { typeset: false }
  };
</script>
<script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-chtml.js" defer></script>
</head>
<body>

<div class="layout">

  <!-- SIDEBAR -->
  <nav class="sidebar">
    <div class="sidebar-logo">
      <span class="emoji">ğŸ”</span>
      <div class="name">Bloomsbury Burger<br>Therapeutics plc</div>
      <div class="sub">pre-seed Â· pre-revenue Â· pre-sanity</div>
    </div>

    <div class="nav-section">
      <div class="nav-label">Pages</div>
      <a href="index.html" class="nav-item active"><span class="icon">ğŸ </span> Overview</a>
      <a href="pipeline.html" class="nav-item"><span class="icon">âš™ï¸</span> Pipeline</a>
      <a href="math.html" class="nav-item"><span class="icon">âˆ‘</span> Mathematics</a>
      <a href="dataset.html" class="nav-item"><span class="icon">ğŸ—„ï¸</span> Dataset</a>
      <a href="console.html" class="nav-item"><span class="icon">ğŸ–¥</span> Lab Console</a>
    </div>

    <div class="sidebar-divider"></div>

    <div class="nav-section">
      <div class="nav-label">On this page</div>
      <a href="#overview" class="nav-item"><span class="icon">Â·</span> Overview</a>
      <a href="#why" class="nav-item"><span class="icon">Â·</span> Why now</a>
      <a href="#pipeline" class="nav-item"><span class="icon">Â·</span> Pipeline</a>
      <a href="#dataset" class="nav-item"><span class="icon">Â·</span> Dataset</a>
      <a href="#resources" class="nav-item"><span class="icon">Â·</span> Resources</a>
      <a href="#glossary" class="nav-item"><span class="icon">Â·</span> Glossary</a>
    </div>

    <div class="sidebar-divider"></div>

    <div class="nav-section">
      <div class="nav-label">Status</div>
      <div class="nav-item" style="cursor:default;">
        <span class="dot green"></span> <span style="font-size:11px;font-family:'DM Mono',monospace;">Atlas loaded</span>
      </div>
      <div class="nav-item" style="cursor:default;">
        <span class="dot blue"></span> <span style="font-size:11px;font-family:'DM Mono',monospace;">Optimising</span>
      </div>
    </div>
  </nav>

  <!-- MAIN -->
  <main class="main">

    <!-- HERO -->
    <div class="hero" id="overview">
      <div class="hero-badge">CAR-T Â· Endometriosis Â· In Silico Discovery</div>
      <h1>Bloomsbury Burger<br><span>Therapeutics</span></h1>
      <p class="hero-desc">
        We are building a dual-target CAR-T therapy guided by single-cell genomics.
        This is not hormone modulation. Not symptom management. This is targeted cellular
        ablation of ectopic lesions â€” informed by a 54-patient transcriptomic atlas and
        a differentiable optimisation formulation we believe is novel.
      </p>
    </div>

    <!-- STATUS ROW -->
    <div class="status-row">
      <div class="status-pill"><span class="dot green"></span> Atlas loaded</div>
      <div class="status-pill"><span class="dot green"></span> 54/54 samples processed</div>
      <div class="status-pill"><span class="dot blue"></span> Optimisation: converged</div>
      <div class="status-pill"><span class="dot yellow"></span> Pair stability: 0.92</div>
    </div>

    <!-- WHY -->
    <section id="why" class="reveal">
      <div class="section-header">
        <div class="section-icon">â“</div>
        <h2>Why endometriosis, why now</h2>
      </div>
      <div class="callout" style="margin-bottom:12px;">
        <p>Endometriosis affects ~10% of people with a uterus worldwide. The current standard of care is surgical resection â€” cutting out the lesions â€” which has a high recurrence rate and is imprecise. Surgeons literally cannot reliably distinguish all pathological tissue from healthy tissue by visual inspection alone.</p>
        <p>The field is chronically underfunded. A 1977 FDA mandate excluded women from early clinical trials and the field has been playing catch-up ever since. Femtech is currently 80% cycle trackers and 20% rebranded thermometers.</p>
        <p><strong>We think a targeted cellular therapy, informed by single-cell genomics, could be a genuinely better solution.</strong> CAR-T has already transformed blood cancer treatment. We're asking: what if we applied the same logic to solid tissue pathology?</p>
      </div>

      <div class="stat-grid" style="margin-top:20px;">
        <div class="stat-card">
          <div class="stat-value"><span data-counter="10" data-suffix="%">10%</span></div>
          <div class="stat-label">Prevalence</div>
          <div class="stat-desc">Global prevalence among people with a uterus. Comparable to diabetes. Receives a fraction of the research funding.</div>
        </div>
        <div class="stat-card">
          <div class="stat-value"><span data-counter="50" data-suffix="%">50%</span></div>
          <div class="stat-label">Recurrence rate</div>
          <div class="stat-desc">Post-surgical recurrence within 5 years. Visual resection misses microscopic pathological deposits.</div>
        </div>
        <div class="stat-card">
          <div class="stat-value"><span style="color:var(--accent);">0</span></div>
          <div class="stat-label">Targeted therapies</div>
          <div class="stat-desc">Zero molecularly-targeted therapies currently approved. The field remains stuck in hormone suppression paradigms.</div>
        </div>
      </div>
    </section>

    <!-- PIPELINE -->
    <section id="pipeline" class="reveal">
      <div class="section-header">
        <div class="section-icon">âš™ï¸</div>
        <h2>Technical pipeline</h2>
      </div>
      <div class="steps">
        <div class="step">
          <div class="step-num">01</div>
          <div class="step-content">
            <h3>Load & QC single-cell data</h3>
            <p>Load raw Cell Ranger output (<code>raw_feature_bc_matrix.h5</code>) for each sample. Filter out empty droplets and dying cells using gene count and mitochondrial read thresholds. Save filtered cells as <code>.h5ad</code> files.</p>
          </div>
        </div>
        <div class="step">
          <div class="step-num">02</div>
          <div class="step-content">
            <h3>Denoise with scVI-VAE</h3>
            <p>Single-cell data is noisy â€” genes drop out randomly. We run scVI (a variational autoencoder) to learn a clean latent representation of each cell's true expression profile. This enables stable binarisation for downstream combinatorial optimisation.</p>
          </div>
        </div>
        <div class="step">
          <div class="step-num">03</div>
          <div class="step-content">
            <h3>Differentiable marker optimisation</h3>
            <p>Instead of brute-force enumeration of ~4.5 million possible marker pairs, we relax the discrete combinatorial search into continuous space using a <strong style="color:var(--accent2);">Gumbel-Softmax reparameterisation</strong>, optimise with gradient descent, then snap back to a hard discrete selection. We believe this specific formulation â€” combining a biomedical specificity objective with a whole-body safety penalty in a jointly differentiable system â€” is novel. <a href="math.html" style="color:var(--accent);text-decoration:none;font-size:12px;">â†’ See full mathematics</a></p>
          </div>
        </div>
        <div class="step">
          <div class="step-num">04</div>
          <div class="step-content">
            <h3>Cross-reference Tabula Sapiens</h3>
            <p>Any surviving marker pairs get checked against the full human cell atlas. Infinite penalty for expression in heart, lung, brain or other critical organs. Only pairs that are truly lesion-specific survive this filter.</p>
          </div>
        </div>
        <div class="step">
          <div class="step-num">05</div>
          <div class="step-content">
            <h3>Output top candidate pairs</h3>
            <p>Gradient descent outputs a ranked top-5 list of dual marker combinations. These get handed off for benchtop feasibility assessment â€” checking whether scFvs (the targeting domains) exist or can be designed for each candidate.</p>
          </div>
        </div>
      </div>
    </section>

    <!-- DATASET -->
    <section id="dataset" class="reveal">
      <div class="section-header">
        <div class="section-icon">ğŸ—„ï¸</div>
        <h2>Dataset â€” GSE213216</h2>
      </div>
      <div class="callout" style="margin-bottom: 16px;">
        <p>We're using the <strong>Human Endometriosis Cell Atlas</strong> published in Nature Genetics (2024). It contains single-cell RNA sequencing data from 54 patient samples across multiple tissue types: ectopic endometrial lesions (endometriomas + peritoneal lesions), eutopic endometrium, and unaffected control tissue.</p>
        <p>Total size: ~15.7GB. Format: Cell Ranger output (10x Genomics). Each sample loads as a barcodes Ã— genes matrix. Integration across samples is performed after QC and batch-aware modelling with scVI.</p>
      </div>
      <div class="tags">
        <span class="tag pink">54 samples</span>
        <span class="tag pink">~15.7 GB</span>
        <span class="tag green">10x Genomics scRNA-seq</span>
        <span class="tag green">Cell Ranger output</span>
        <span class="tag blue">Ectopic lesions</span>
        <span class="tag blue">Eutopic endometrium</span>
        <span class="tag blue">Control tissue</span>
        <span class="tag purple">Nature Genetics 2024</span>
      </div>
    </section>

    <!-- RESOURCES -->
    <section id="resources" class="reveal">
      <div class="section-header">
        <div class="section-icon">ğŸ“š</div>
        <h2>Key resources</h2>
      </div>
      <div class="resources">
        <a href="https://www.nature.com/articles/s41588-024-01873-w" target="_blank" class="resource-card">
          <div class="r-type">ğŸ“„ Paper</div>
          <div class="r-title">Human Endometriosis Cell Atlas</div>
          <div class="r-desc">Nature Genetics 2024. The dataset we're mining. Single-cell atlas of endometriosis lesions across 54 patients.</div>
          <div class="r-link">nature.com â†’</div>
        </a>
        <a href="https://www.nature.com/articles/s41586-019-1546-z" target="_blank" class="resource-card">
          <div class="r-type">ğŸ“„ Paper</div>
          <div class="r-title">CAR-T cell therapy blueprint</div>
          <div class="r-desc">Nature 2019. The conceptual framework we're adapting for endometriosis â€” using CAR-T to target solid tissue.</div>
          <div class="r-link">nature.com â†’</div>
        </a>
        <a href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE213216" target="_blank" class="resource-card">
          <div class="r-type">ğŸ—„ï¸ Dataset</div>
          <div class="r-title">GSE213216 on GEO</div>
          <div class="r-desc">NCBI GEO page for the endometriosis atlas. Download the raw data here.</div>
          <div class="r-link">ncbi.nlm.nih.gov â†’</div>
        </a>
        <a href="https://www.jnj.com/media-center/press-releases/johnson-johnsons-dual-targeting-car-t-cell-therapy-shows-encouraging-first-results-in-large-b-cell-lymphoma" target="_blank" class="resource-card">
          <div class="r-type">ğŸ“° News</div>
          <div class="r-title">Dual-targeting CAR-T â€” J&J results</div>
          <div class="r-desc">Proof that dual-target CAR-T works in humans. Encouraging early results in large B-cell lymphoma.</div>
          <div class="r-link">jnj.com â†’</div>
        </a>
        <a href="math.html" class="resource-card">
          <div class="r-type">âˆ‘ Mathematics</div>
          <div class="r-title">Our formulation â€” full derivation</div>
          <div class="r-desc">The complete mathematical treatment of our differentiable marker optimisation. Possibly novel in the differentiable programming literature.</div>
          <div class="r-link">math.html â†’</div>
        </a>
        <a href="https://www.sc-best-practices.org" target="_blank" class="resource-card">
          <div class="r-type">ğŸ“– Guide</div>
          <div class="r-title">Single-cell best practices</div>
          <div class="r-desc">The definitive guide to scRNA-seq analysis. QC, normalisation, integration, everything.</div>
          <div class="r-link">sc-best-practices.org â†’</div>
        </a>
      </div>
    </section>

    <!-- GLOSSARY -->
    <section id="glossary" class="reveal">
      <div class="section-header">
        <div class="section-icon">ğŸ“–</div>
        <h2>Glossary â€” for the new people</h2>
      </div>
      <div class="faq">
        <div class="faq-item">
          <div class="faq-q" onclick="toggle(this)">What is a CAR-T cell? <span class="chevron">â–¼</span></div>
          <div class="faq-a">CAR-T stands for Chimeric Antigen Receptor T-cell. It's a type of immune cell (T-cell) that we genetically engineer to express a synthetic receptor (the CAR) on its surface. This receptor recognises specific proteins on target cells and triggers the T-cell to destroy them. It's already used in blood cancers and has transformed treatment for some patients.</div>
        </div>
        <div class="faq-item">
          <div class="faq-q" onclick="toggle(this)">What is scRNA-seq? <span class="chevron">â–¼</span></div>
          <div class="faq-a">Single-cell RNA sequencing. It lets us measure which genes are switched on or off in thousands of individual cells simultaneously. Traditional RNA-seq gives you an average across millions of cells â€” scRNA-seq gives you a snapshot of every single cell independently. This is how we can identify what makes ectopic endometrial cells different from healthy ones.</div>
        </div>
        <div class="faq-item">
          <div class="faq-q" onclick="toggle(this)">What's ectopic vs eutopic endometrium? <span class="chevron">â–¼</span></div>
          <div class="faq-a">Eutopic endometrium is the normal uterine lining â€” where it's supposed to be. Ectopic means "out of place" â€” in endometriosis, endometrial-like tissue grows outside the uterus (on the ovaries, peritoneum, fallopian tubes, etc). These lesions are what we want to target with the CAR-T. Our targets need to be present in ectopic tissue but NOT in eutopic tissue or healthy organs.</div>
        </div>
        <div class="faq-item">
          <div class="faq-q" onclick="toggle(this)">What is scVI? <span class="chevron">â–¼</span></div>
          <div class="faq-a">scVI is a deep learning model (variational autoencoder) designed specifically for single-cell data. Single-cell measurements are very noisy â€” genes randomly drop out and counts are sparse. scVI learns a cleaner latent representation of each cell's true biology by modelling the technical noise explicitly. We use it to denoise the data before doing marker discovery.</div>
        </div>
        <div class="faq-item">
          <div class="faq-q" onclick="toggle(this)">What is Tabula Sapiens? <span class="chevron">â–¼</span></div>
          <div class="faq-a">A whole-human cell atlas â€” essentially a map of gene expression across every major cell type in the human body. We use it as a safety filter. If a candidate marker is also expressed in heart cells, lung cells, or neurons, we throw it out immediately â€” we don't want the CAR-T attacking those.</div>
        </div>
        <div class="faq-item">
          <div class="faq-q" onclick="toggle(this)">Why dual targeting? <span class="chevron">â–¼</span></div>
          <div class="faq-a">A CAR-T that targets one marker is risky â€” if that marker appears anywhere else in the body, you get off-target toxicity. A dual-target CAR only activates when BOTH markers are present simultaneously (like an AND gate). This is far more specific, because the probability of two markers co-occurring in healthy tissue is much lower than either one alone. J&J recently showed this works in humans.</div>
        </div>
        <div class="faq-item">
          <div class="faq-q" onclick="toggle(this)">What's Gumbel-Softmax and why does it matter? <span class="chevron">â–¼</span></div>
          <div class="faq-a">The marker selection problem is discrete: you either include a gene or you don't. Gradient descent requires a continuous, differentiable objective. The Gumbel-Softmax trick lets us relax discrete categorical choices into soft continuous probability vectors, run gradient descent, then anneal the temperature back to recover a hard discrete selection. This makes searching the ~4.5M pair space tractable. <a href="math.html" style="color:var(--accent);">Full math here â†’</a></div>
        </div>
      </div>
    </section>

    <div class="footer">
      <span>bloomsbury burger therapeutics plc Â© 2026</span>
      <span>pre-seed Â· pre-revenue Â· pre-sanity</span>
    </div>

  </main>
</div>

<script src="script.js"></script>
</body>
</html>
